 | • レポートコード：GIR201115349 • 出版社/出版日：GlobalInfoResearch / 2020年10月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、109ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本書では、更年期治療・血管運動症状の世界市場を調査対象にし、更年期治療・血管運動症状の市場概要、企業情報、企業別売上・市場シェア、地域別市場分析（北米、アメリカ、ヨーロッパ、アジア、日本、中国、南米、中東・アフリカ）、種類別分析（エステトロール、フェゾリネタント、FP-101、HBN-2、その他）、用途別分析（病院、在宅医療、クリニック）、市場予測（2021年～2025年）情報などを整理しました。 ・市場概要 ・企業情報：Amgen Inc.、Radius Health, Inc.、MenoGeniX, Inc.、EndoCeutics, Inc.、Pivot Pharmaceuticals Inc、Euroscreen S.A.、Pherin Pharmaceuticals, Inc.、Mithra Pharmaceuticals S.A.、TherapeuticsMD, Inc. ・企業別売上、市場シェア ・更年期治療・血管運動症状の地域別市場分析 ・更年期治療・血管運動症状の北米市場規模2015-2020：アメリカ、カナダ、メキシコ ・更年期治療・血管運動症状のヨーロッパ市場規模2015-2020：ドイツ、イギリス、フランス、ロシアなど ・更年期治療・血管運動症状のアジア市場規模2015-2020：日本、中国、韓国、インド、東南アジアなど ・更年期治療・血管運動症状の南米市場規模2015-2020：ブラジル、アルゼンチンなど ・更年期治療・血管運動症状の中東・アフリカ市場規模2015-2020：サウジアラビア、トルコ、エジプト、南アフリカなど ・更年期治療・血管運動症状の種類別市場規模2015-2020：エステトロール、フェゾリネタント、FP-101、HBN-2、その他 ・更年期治療・血管運動症状の用途別市場規模2015-2020：病院、在宅医療、クリニック ・更年期治療・血管運動症状の世界市場予測2021-2025：地域別、種類別、用途別 ・調査の結果・結論 |
Market Overview
The global Vasomotor Symptoms of Menopause Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Vasomotor Symptoms of Menopause Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Vasomotor Symptoms of Menopause Treatment market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Vasomotor Symptoms of Menopause Treatment market has been segmented into:
Estetrol
Fezolinetant
FP-101
HBN-2
Others
By Application, Vasomotor Symptoms of Menopause Treatment has been segmented into:
Hospital
Homecare
Clinic
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Vasomotor Symptoms of Menopause Treatment market presented in the report. This section sheds light on the sales growth of different regional and country-level Vasomotor Symptoms of Menopause Treatment markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Vasomotor Symptoms of Menopause Treatment market.
The report offers in-depth assessment of the growth and other aspects of the Vasomotor Symptoms of Menopause Treatment market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Vasomotor Symptoms of Menopause Treatment Market Share Analysis
Vasomotor Symptoms of Menopause Treatment competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Vasomotor Symptoms of Menopause Treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Vasomotor Symptoms of Menopause Treatment sales, revenue and market share for each player covered in this report.
The major players covered in Vasomotor Symptoms of Menopause Treatment are:
Amgen Inc.
Radius Health, Inc.
MenoGeniX, Inc.
EndoCeutics, Inc.
Pivot Pharmaceuticals Inc
Euroscreen S.A.
Pherin Pharmaceuticals, Inc.
Mithra Pharmaceuticals S.A.
TherapeuticsMD, Inc.
Table of Contents
1 Vasomotor Symptoms of Menopause Treatment Market Overview
1.1 Product Overview and Scope of Vasomotor Symptoms of Menopause Treatment
1.2 Classification of Vasomotor Symptoms of Menopause Treatment by Type
1.2.1 Global Vasomotor Symptoms of Menopause Treatment Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type in 2019
1.2.3 Estetrol
1.2.4 Fezolinetant
1.2.5 FP-101
1.2.6 HBN-2
1.2.7 Others
1.3 Global Vasomotor Symptoms of Menopause Treatment Market by Application
1.3.1 Overview: Global Vasomotor Symptoms of Menopause Treatment Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospital
1.3.3 Homecare
1.3.4 Clinic
1.4 Global Vasomotor Symptoms of Menopause Treatment Market by Regions
1.4.1 Global Vasomotor Symptoms of Menopause Treatment Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Vasomotor Symptoms of Menopause Treatment (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Vasomotor Symptoms of Menopause Treatment Status and Prospect (2015-2025)
2 Company Profiles
2.1 Amgen Inc.
2.1.1 Amgen Inc. Details
2.1.2 Amgen Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Amgen Inc. SWOT Analysis
2.1.4 Amgen Inc. Product and Services
2.1.5 Amgen Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.2 Radius Health, Inc.
2.2.1 Radius Health, Inc. Details
2.2.2 Radius Health, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Radius Health, Inc. SWOT Analysis
2.2.4 Radius Health, Inc. Product and Services
2.2.5 Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.3 MenoGeniX, Inc.
2.3.1 MenoGeniX, Inc. Details
2.3.2 MenoGeniX, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 MenoGeniX, Inc. SWOT Analysis
2.3.4 MenoGeniX, Inc. Product and Services
2.3.5 MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.4 EndoCeutics, Inc.
2.4.1 EndoCeutics, Inc. Details
2.4.2 EndoCeutics, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 EndoCeutics, Inc. SWOT Analysis
2.4.4 EndoCeutics, Inc. Product and Services
2.4.5 EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.5 Pivot Pharmaceuticals Inc
2.5.1 Pivot Pharmaceuticals Inc Details
2.5.2 Pivot Pharmaceuticals Inc Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Pivot Pharmaceuticals Inc SWOT Analysis
2.5.4 Pivot Pharmaceuticals Inc Product and Services
2.5.5 Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.6 Euroscreen S.A.
2.6.1 Euroscreen S.A. Details
2.6.2 Euroscreen S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Euroscreen S.A. SWOT Analysis
2.6.4 Euroscreen S.A. Product and Services
2.6.5 Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.7 Pherin Pharmaceuticals, Inc.
2.7.1 Pherin Pharmaceuticals, Inc. Details
2.7.2 Pherin Pharmaceuticals, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Pherin Pharmaceuticals, Inc. SWOT Analysis
2.7.4 Pherin Pharmaceuticals, Inc. Product and Services
2.7.5 Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.8 Mithra Pharmaceuticals S.A.
2.8.1 Mithra Pharmaceuticals S.A. Details
2.8.2 Mithra Pharmaceuticals S.A. Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Mithra Pharmaceuticals S.A. SWOT Analysis
2.8.4 Mithra Pharmaceuticals S.A. Product and Services
2.8.5 Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
2.9 TherapeuticsMD, Inc.
2.9.1 TherapeuticsMD, Inc. Details
2.9.2 TherapeuticsMD, Inc. Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 TherapeuticsMD, Inc. SWOT Analysis
2.9.4 TherapeuticsMD, Inc. Product and Services
2.9.5 TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.2.2 Top 10 Vasomotor Symptoms of Menopause Treatment Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Market Share by Regions
4.2 North America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.3 Europe Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.5 South America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5 North America Vasomotor Symptoms of Menopause Treatment Revenue by Countries
5.1 North America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
5.2 USA Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5.3 Canada Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
5.4 Mexico Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Countries
6.1 Europe Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
6.2 Germany Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.3 UK Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.4 France Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.5 Russia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
6.6 Italy Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Countries
7.1 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
7.2 China Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.3 Japan Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.4 Korea Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.5 India Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
8 South America Vasomotor Symptoms of Menopause Treatment Revenue by Countries
8.1 South America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
8.2 Brazil Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
8.3 Argentina Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Vasomotor Symptoms of Menopause Treatment by Countries
9.1 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
9.2 Saudi Arabia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.3 UAE Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.4 Egypt Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
9.5 South Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Vasomotor Symptoms of Menopause Treatment Revenue and Market Share by Type (2015-2020)
10.2 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Type (2019-2024)
10.3 Estetrol Revenue Growth Rate (2015-2025)
10.4 Fezolinetant Revenue Growth Rate (2015-2025)
10.5 FP-101 Revenue Growth Rate (2015-2025)
10.6 HBN-2 Revenue Growth Rate (2015-2025)
10.7 Others Revenue Growth Rate (2015-2025)
11 Global Vasomotor Symptoms of Menopause Treatment Market Segment by Application
11.1 Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application (2015-2020)
11.2 Vasomotor Symptoms of Menopause Treatment Market Forecast by Application (2019-2024)
11.3 Hospital Revenue Growth (2015-2020)
11.4 Homecare Revenue Growth (2015-2020)
11.5 Clinic Revenue Growth (2015-2020)
12 Global Vasomotor Symptoms of Menopause Treatment Market Size Forecast (2021-2025)
12.1 Global Vasomotor Symptoms of Menopause Treatment Market Size Forecast (2021-2025)
12.2 Global Vasomotor Symptoms of Menopause Treatment Market Forecast by Regions (2021-2025)
12.3 North America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.4 Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.6 South America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Vasomotor Symptoms of Menopause Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Amgen Inc. Corporate Information, Location and Competitors
Table 6. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 7. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 8. Amgen Inc. SWOT Analysis
Table 9. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 10. Amgen Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Radius Health, Inc. Corporate Information, Location and Competitors
Table 12. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 13. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2018-2019)
Table 14. Radius Health, Inc. SWOT Analysis
Table 15. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 16. Radius Health, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. MenoGeniX, Inc. Corporate Information, Location and Competitors
Table 18. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 19. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 20. MenoGeniX, Inc. SWOT Analysis
Table 21. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 22. MenoGeniX, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. EndoCeutics, Inc. Corporate Information, Location and Competitors
Table 24. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 25. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 26. EndoCeutics, Inc. SWOT Analysis
Table 27. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 28. EndoCeutics, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Pivot Pharmaceuticals Inc Corporate Information, Location and Competitors
Table 30. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Major Business
Table 31. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 32. Pivot Pharmaceuticals Inc SWOT Analysis
Table 33. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 34. Pivot Pharmaceuticals Inc Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Euroscreen S.A. Corporate Information, Location and Competitors
Table 36. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Major Business
Table 37. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 38. Euroscreen S.A. SWOT Analysis
Table 39. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 40. Euroscreen S.A. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Pherin Pharmaceuticals, Inc. Corporate Information, Location and Competitors
Table 42. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 43. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 44. Pherin Pharmaceuticals, Inc. SWOT Analysis
Table 45. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 46. Pherin Pharmaceuticals, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Mithra Pharmaceuticals S.A. Corporate Information, Location and Competitors
Table 48. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Major Business
Table 49. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 50. Mithra Pharmaceuticals S.A. SWOT Analysis
Table 51. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 52. Mithra Pharmaceuticals S.A. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. TherapeuticsMD, Inc. Corporate Information, Location and Competitors
Table 54. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Major Business
Table 55. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Total Revenue (USD Million) (2017-2018)
Table 56. TherapeuticsMD, Inc. SWOT Analysis
Table 57. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Product and Solutions
Table 58. TherapeuticsMD, Inc. Vasomotor Symptoms of Menopause Treatment Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Players (2015-2020)
Table 60. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Players (2015-2020)
Table 61. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Regions (2015-2020)
Table 62. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Regions (2015-2020)
Table 63. North America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
Table 64. North America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Table 65. Europe Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Countries (2015-2020)
Table 66. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Countries (2015-2020)
Table 67. South America Vasomotor Symptoms of Menopause Treatment Revenue by Countries (2015-2020)
Table 68. South America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Table 69. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Countries (2015-2020)
Table 70. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Table 71. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) by Type (2015-2020)
Table 72. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Type (2015-2020)
Table 73. Global Vasomotor Symptoms of Menopause Treatment Revenue Forecast by Type (2021-2025)
Table 74. Global Vasomotor Symptoms of Menopause Treatment Revenue by Application (2015-2020)
Table 75. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Application (2015-2020)
Table 76. Global Vasomotor Symptoms of Menopause Treatment Revenue Forecast by Application (2021-2025)
Table 77. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Vasomotor Symptoms of Menopause Treatment Picture
Figure 2. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Type in 2019
Figure 3. Estetrol Picture
Figure 4. Fezolinetant Picture
Figure 5. FP-101 Picture
Figure 6. HBN-2 Picture
Figure 7. Others Picture
Figure 8. Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Application in 2019
Figure 9. Hospital Picture
Figure 10. Homecare Picture
Figure 11. Clinic Picture
Figure 12. Global Vasomotor Symptoms of Menopause Treatment Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Vasomotor Symptoms of Menopause Treatment Revenue Market Share in 2019
Figure 21. Global Top 10 Players Vasomotor Symptoms of Menopause Treatment Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Regions (2015-2020)
Figure 25. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Regions in 2018
Figure 26. North America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 27. Europe Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 29. South America Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 31. North America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Figure 32. North America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries in 2019
Figure 33. USA Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 34. Canada Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 36. Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries in 2019
Figure 38. Germany Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 39. UK Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 40. France Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 41. Russia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 42. Italy Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries in 2019
Figure 45. China Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 46. Japan Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 47. Korea Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 48. India Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 50. South America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Figure 51. South America Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries in 2019
Figure 52. Brazil Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 57. UAE Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Vasomotor Symptoms of Menopause Treatment Revenue and Growth Rate (2015-2020)
Figure 60. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Type (2015-2020)
Figure 61. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Type in 2019
Figure 62. Global Vasomotor Symptoms of Menopause Treatment Market Share Forecast by Type (2021-2025)
Figure 63. Global Estetrol Revenue Growth Rate (2015-2020)
Figure 64. Global Fezolinetant Revenue Growth Rate (2015-2020)
Figure 65. Global FP-101 Revenue Growth Rate (2015-2020)
Figure 66. Global HBN-2 Revenue Growth Rate (2015-2020)
Figure 67. Global Others Revenue Growth Rate (2015-2020)
Figure 68. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Application (2015-2020)
Figure 69. Global Vasomotor Symptoms of Menopause Treatment Revenue Share by Application in 2019
Figure 70. Global Vasomotor Symptoms of Menopause Treatment Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospital Revenue Growth Rate (2015-2020)
Figure 72. Global Homecare Revenue Growth Rate (2015-2020)
Figure 73. Global Clinic Revenue Growth Rate (2015-2020)
Figure 74. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Vasomotor Symptoms of Menopause Treatment Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Vasomotor Symptoms of Menopause Treatment Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
Figure 78. Europe Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
Figure 80. South America Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Vasomotor Symptoms of Menopause Treatment Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel
閉経薬の世界市場 2020年 Market Overview The global Menopause Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Menopause Drugs market report…- 軟骨無形成症治療の世界市場 2020年 Market Overview The global Achondroplasia Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Achondroplasia Treat…
- 不安障害及びうつ病治療の世界市場 2020年 Market Overview The Anxiety Disorder and Depression Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value…
- 酒さ治療の世界市場 2020年 Market Overview The global Rosacea Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.1% in the forecast period of 2020 to 2025 and will expected to reach USD 1721.7 million by 2025, from USD 1526 million in 2019. The Rosacea Treatment ma…
- 第IX因子欠乏症治療の世界市場 2020年 Market Overview The global Factor IX Deficiency Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Factor IX Defi…